Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 6:50 pm Purchase |
2025-03-31 | 13G | Solid Biosciences Inc. SLDB |
Invus Public Equities, L.P. | 7,415,905 9.600% |
3,666,864 (+97.81%) |
Filing History |
| 2025-04-17 4:30 pm Purchase |
2023-12-31 | 13G | Nanobiotix S.A. NBTX |
Invus Public Equities, L.P. | 4,232,829 8.900% |
4,232,829 (New Position) |
Filing History |
| 2025-04-11 4:43 pm Purchase |
2022-09-02 | 13G | ABIVAX SA ABVX |
Invus Public Equities, L.P. | 5,403,985 8.500% |
5,403,985 (New Position) |
Filing History |
| 2025-03-31 5:04 pm Purchase |
2024-10-17 | 13G | Inventiva S.A. IVA |
Invus Public Equities, L.P. | 7,407,406 7.800% |
7,407,406 (New Position) |
Filing History |
| 2025-02-12 4:30 pm Purchase |
2024-12-31 | 13G | Solid Biosciences Inc. SLDB |
Invus Public Equities, L.P. | 3,749,041 9.400% |
1,000,000 (+36.38%) |
Filing History |
| 2025-02-12 4:30 pm Unchanged |
2024-12-31 | 13G | Vigil Neuroscience, Inc. VIGL |
Invus Public Equities, L.P. | 1,991,038 4.900% |
0 (Unchanged) |
Filing History |
| 2025-02-12 4:30 pm Sale |
2024-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS |
Invus Public Equities, L.P. | 1,063,829 3.800% |
-2,587,372 (-70.86%) |
Filing History |
| 2025-02-12 4:30 pm Sale |
2024-12-31 | 13G | Gossamer Bio, Inc. GOSS |
Invus Public Equities, L.P. | 6,258,880 2.800% |
-8,072,642 (-56.33%) |
Filing History |
| 2025-02-12 4:30 pm Sale |
2024-12-31 | 13G | Scholar Rock Holding Corporation SRRK |
Invus Public Equities, L.P. | 10,825,013 11.400% |
-2,009,433 (-15.66%) |
Filing History |
| 2024-11-12 4:58 pm Purchase |
2024-09-30 | 13G | Solid Biosciences Inc. SLDB |
Invus Public Equities, L.P. | 2,749,041 7.100% |
240,898 (+9.60%) |
Filing History |
| 2024-11-12 4:40 pm Sale |
2024-09-30 | 13G | Gossamer Bio, Inc. GOSS |
Invus Public Equities, L.P. | 14,331,522 6.300% |
-27,358 (-0.19%) |
Filing History |
| 2024-11-12 4:31 pm Purchase |
2024-09-30 | 13G | Silence Therapeutics plc SLN |
Invus Public Equities, L.P. | 8,495,310 6.100% |
156,453 (+1.88%) |
Filing History |
| 2024-11-12 4:30 pm Purchase |
2024-09-30 | 13G | Syros Pharmaceuticals, Inc. SYRS |
Invus Public Equities, L.P. | 3,651,201 9.900% |
82,359 (+2.31%) |
Filing History |
| 2024-11-12 4:30 pm Sale |
2024-09-30 | 13G | GlycoMimetics, Inc. GLYC |
Invus Public Equities, L.P. | 1,965,114 3.000% |
-3,323,394 (-62.84%) |
Filing History |
| 2024-09-26 4:30 pm Purchase |
2024-09-16 | 13G | Bicara Therapeutics Inc. Common Stock BCAX |
Invus Public Equities, L.P. | 3,072,827 5.700% |
3,072,827 (New Position) |
Filing History |
| 2024-08-15 5:01 pm Sale |
2024-08-13 | 13G | GlycoMimetics, Inc. GLYC |
Invus Public Equities, L.P. | 5,288,508 8.200% |
-3,300,556 (-38.43%) |
Filing History |
| 2024-08-12 5:02 pm Purchase |
2024-08-01 | 13G | Vigil Neuroscience, Inc. VIGL |
Invus Public Equities, L.P. | 1,991,038 5.300% |
1,991,038 (New Position) |
Filing History |
| 2024-08-02 6:51 pm Purchase |
2024-07-25 | 13G | Silence Therapeutics plc SLN |
Invus Public Equities, L.P. | 8,338,857 6.000% |
8,338,857 (New Position) |
Filing History |
| 2024-08-02 6:41 pm Purchase |
2024-07-25 | 13G | IGM Biosciences, Inc. IGMS |
Invus Public Equities, L.P. | 3,330,422 9.900% |
3,330,422 (New Position) |
Filing History |
| 2024-08-02 6:39 pm Purchase |
2024-07-25 | 13G | Syros Pharmaceuticals, Inc. SYRS |
Invus Public Equities, L.P. | 3,568,842 9.900% |
3,568,842 (New Position) |
Filing History |